| Outcome Measures: |
Primary: Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks), 6 times, screening, week 0, week 13-26-39-52|Change in weight from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks), 6 times, screening, week 0, week 13-26-39-52 | Secondary: Change in blood pressure from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks), 6 times, screening, week 0, week 13-26-39-52|Change in quality of life from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks), Quality of life questionnaires SF-36 en EQ-5D will be used., 3 times, week 0, 26, 52|Change in NEAT from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks), Neat will be measured using ActivPal accelerometer during one week., 3 times, week 0, 26, 52|Health-care related costs, At baseline, after 26 weeks and after 52 weeks
|
